HCC and angiogenesis: possible targets and future directions

Area of Science:

• Oncology
• Hepatology
• Vascular Biology

Background:

• Hepatocellular carcinoma (HCC) is the most common primary liver cancer.
• HCC is often resistant to systemic therapies and recurs after local treatments.
• Tumor growth depends on angiogenesis, with Vascular Endothelial Growth Factor (VEGF) being critical.

Purpose of the Study:

• To review the role of VEGF in HCC development and treatment.
• To discuss the significance of anti-VEGF therapy in advanced HCC.
• To explore future directions for targeted therapies in HCC.

Main Methods:

• Review of existing literature on HCC, VEGF, and antiangiogenic therapies.
• Analysis of the impact of VEGF on the tumor microenvironment.
• Examination of clinical trial data for sorafenib in advanced HCC.

Main Results:

• Tumor angiogenesis, driven by VEGF, creates an abnormal microenvironment.
• Anti-VEGF therapy with sorafenib is the first systemic treatment to improve survival in advanced HCC.
• Abnormal tumor vasculature and hypoxia select for more aggressive HCC phenotypes.

Conclusions:

• Targeted antiangiogenic agents hold promise for improving survival in HCC.
• Further research into novel targeted therapies is crucial for advancing HCC treatment.
• Understanding the tumor microenvironment is key to developing effective HCC therapies.